Tarsus Pharmaceuticals (TARS) Change in Acquisitions & Divestments (2022 - 2026)

Tarsus Pharmaceuticals' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $74.1 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 18.82% year-over-year to $74.1 million in Q1 2026; TTM through Mar 2026 was $344.6 million, a 113.11% increase from a year earlier, with the FY2025 full-year figure at $361.8 million, up 395.62% from the prior year.
• Change in Acquisitions & Divestments fell to $74.1 million in Q1 2026 per TARS's latest filing, from $92.1 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $99.5 million in Q3 2025 and bottomed at $2.5 million in Q1 2024.
• The 5-year median for Change in Acquisitions & Divestments is $46.0 million (2023), against an average of $49.2 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 93.8% in 2024 and surged 3548.72% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $5.3 million in 2022, then soared by 235.84% to $17.8 million in 2023, then surged by 98.68% to $35.5 million in 2024, then surged by 159.64% to $92.1 million in 2025, then dropped by 19.58% to $74.1 million in 2026.
• Per Business Quant, the three latest TARS Change in Acquisitions & Divestments figures stand at $74.1 million (Q1 2026), $92.1 million (Q4 2025), and $99.5 million (Q3 2025).